HighTower Advisors’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.13M Sell
9,781
-325
-3% -$35K ﹤0.01% 2190
2026
Q2
$879K Sell
10,106
-1,827
-15% -$110K ﹤0.01% 2326
2026
Q1
$481K Buy
11,933
+122
+1% +$4.56K ﹤0.01% 2748
2025
Q4
$411K Sell
11,811
-35,093
-75% -$2.76M ﹤0.01% 2785
2025
Q3
$3.9M Sell
46,904
-2,674
-5% -$194K ﹤0.01% 1254
2025
Q2
$3.64M Sell
49,578
-50,674
-51% -$3.67M ﹤0.01% 1238
2025
Q1
$11.5M Buy
100,252
+6,575
+7% +$400K 0.02% 705
2024
Q4
$4.72M Buy
93,677
+22,011
+31% +$1.15M 0.01% 1073
2024
Q3
$3.31M Sell
71,666
-5,839
-8% -$207K ﹤0.01% 1227
2024
Q2
$2.52M Buy
77,505
+5,137
+7% +$141K ﹤0.01% 1326
2024
Q1
$1.82M Buy
72,368
+55,042
+318% +$1.3M ﹤0.01% 1477
2023
Q4
$570K Sell
17,326
-4,025
-19% -$111K ﹤0.01% 2223
2023
Q3
$580K Buy
+21,351
New +$618K ﹤0.01% 2129
2018
Q1
– Sell
-11,832
Closed -$215K – 2214
2017
Q4
$215K Buy
+11,832
New +$214K ﹤0.01% 1876

Other funds holding CORT

HighTower Advisors's CORT Position: Q3 2026 in Review

HighTower Advisors reduced its Corcept Therapeutics (CORT) stake by 3.2% in Q3 2026, selling an estimated $35K and leaving 9,781 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2190.

HighTower Advisors first reported a position in CORT in Q4 2017 and has held it in 14 quarters since. The position peaked at $11.5M in Q1 2025. 403 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • HighTower Advisors held 9,781 shares of Corcept Therapeutics worth $1.13M as of Q3 2026.
  • HighTower Advisors sold 325 Corcept Therapeutics shares in Q3 2026, an estimated $35K.
  • Corcept Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #2190 holding.
  • HighTower Advisors first reported a position in Corcept Therapeutics in Q4 2017 and has held it in 14 quarters since.
  • HighTower Advisors's Corcept Therapeutics position peaked at $11.5M in Q1 2025.
  • 403 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.